Engineered immune cells take on recurrent B-Cell cancers
NCT ID NCT02153580
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new cellular immunotherapy for adults with certain B-cell cancers (like lymphomas and leukemias) that have come back. Researchers take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and infuse them back after chemotherapy. The main goal is to find the safest dose and understand side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- modified immune cells (CAR T-cells) targeting CD19
- What this could lead to
- If successful, this could lead to a new treatment option for patients with certain B-cell cancers that have come back after other treatments.
- What could go wrong
- This is an early phase 1 trial with only 37 participants, so results may not apply to everyone. There are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a new drug combo shield young hearts from transplant complications?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma